In contrast, M-Gef-CD133 showed much higher toxicity toward CD133+ lung CSCs than toward CD133− lung cancer cells, indicating that M-Gef-CD133 overcame the gefitinib resistance. This evidence concerns the gene PROM1 and lung cancer.